Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

STK33 (Q9BYT3) - Overview - Molecular Target Synopsis

Protein


STK33, Serine/threonine-protein kinase 33
Enzyme Classification 2.7.11.1
UniProt Q9BYT3

Also Known as STK33_HUMAN, STK33

Serine/threonine protein kinase which phosphorylates VIME. May play a specific role in the dynamic behavior of the intermediate filament cytoskeleton by phosphorylation of VIME (By similarity). Not essential for the survival of KRAS-dependent AML cell lines. Interacts with VIME.

Isoforms / Transcripts (Protein Coding)


Sub-cellular localization


UniProt: STK33 is active in the following subcellular-locations: cytoplasm, perinuclear region.
GO terms: STK33 is active in the following subcellular-locations: cytoplasm, nucleus, perinuclear region of cytoplasm.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project STK33 has gain in 0 cell-lines, loss in 3 cell-lines and no signal in 1000 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: HOP_62, U251, SNB_19

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: NCI-H2196, HM7, A-375

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: NHLF, HSMM, HMEC

(see details)

RNA Interference


STK33 was reported in the following RNAI studies:

Cell - Large Scale Profiling of Kinase Dependencies in Cancer Cell Lines, the highest RNAi cell lines are: PCI30, PL5. (see details)

3D Structures


At greater than 35% identity similarity to STK33 there are:
109 structures (155 chains) solved
88 are solved in complex with at least one small molecule ligand
1 are solved with an approved drug

STK33 is solved in complex with the approved drug(s):

AMP/ADENOSINE PHOSPHATE (4Y5Q_A).

(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


STK33 has been screened with 344 compounds (568 bioactivities), 27 compounds have bioactivities that show binding affinity of <= 500nM (32 bioactivities). (see details)